Paper: Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

As the COVID pandemic continues, we are gaining increasing insight re: vaccine efficacy in our unique patient population. This observational study shows that 70% of MDS/AML patients convert to seropositivity after 1 dose and 95.7% after a second dose, with significant higher titers after the second dose. Neutropenia and lymphopenia did not affect the seropositivity rate.

Read the full article here

Related Articles